• Anticonvulsants;
  • Topiramate;
  • Phenytoin;
  • Carbamazepine;
  • Valproate;
  • Lamotrigine;
  • Gabapentin;
  • Vigabatrin;
  • Oxcarbazepine;
  • Drug therapy;
  • Pharmacokinetics;
  • Drug monitoring;
  • Drug toxicity

Summary: Standard antiepileptic drugs (AEDs) have a number of pharmacokinetic shortcomings, and AEDs with more favorable profiles would be preferred. The pharmacokinetics and interaction profile of the recently developed AED topiramate (TPM), is reviewed and compared with those of other newer AEDs including lamotrigine (LTG), gabapentin (GBP), vigabatrin (VGB), and oxcarbazepine (OCBZ). Although none of these agents meets all of the criteria of the “ideal” AED from the pharmacokinetic standpoint, a number of these drugs, including TPM, have desirable properties that distinguish them from the older AEDs and should contribute to their clinical utility.